In
this Perspective we show how an expansion of the scope and impact
of biocatalysis in industrial organic synthesis is enabled by streamlining
the underpinning biocatalyst and bioprocess engineering. We begin
by discussing how the underlying need for waste reduction and high
(enantio)selectivities fostered the introduction of biocatalysis as
a sustainable technology for the industrial synthesis of active pharmaceutical
ingredients (APIs). We continue by showing how advances in molecular
biology, in particular gene sequencing and protein engineering, enabled
the development of more and better enzymes, thereby broadening the
industrial scope of biocatalysis. Further process improvements are
provided through protein engineering for enzyme immobilization and
integration of enzyme production with in vivo immobilization.
Finally, the use of immobilized enzymes in continuous operation (biocatalysis
in flow) facilitates the sequential integration of multi-step reactions
into enzymatic or chemo-enzymatic cascade processes, thus enabling
the complete, cost-effective, and environmentally attractive production
of APIs.